How did CBIO's Momentum indicator behave recently?

The Momentum Indicator moved below the 0 level on May 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CBIO as a result. In 81 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.

What is the significance of the 50-day moving average indicator for CBIO?

CBIO moved below its 50-day moving average on June 02, 2026 date and that indicates a change from an upward trend to a downward trend. In 37 of 40 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

What is the significance of the 10-day moving average indicator for CBIO?

The 10-day moving average for CBIO crossed bearishly below the 50-day moving average on June 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

What does a 3-day price advance indicate for CBIO?

Following a +8.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where CBIO advanced for three days, in 192 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

CBIO

AS OF

Jun 15, 04:59 PM (EDT)

Price

$18.14

Change

+$0.22 (+1.23%)

Capitalization

498.28M

45 days until earnings call

Intraday BUY SELL Signals

OUR PRODUCTS

MOBILE APPS

GENERAL INFO

Help

+Compare

CBIO

Stock ticker: NASDAQ

AS OF

Jun 15, 04:59 PM (EDT)

Price

$18.14

Change

+$0.22 (+1.23%)

Capitalization

498.28M

CBIO

Stock ticker: NASDAQ

PRICE

CHANGE

CAPITALIZATION

CBIO stock forecast, quote, news & analysis

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody... Show more

Industry: #Biotechnology

Get AI intraday signals

CBIO

Setup

Daily Signal:

Description

Gain/Loss:

A.I.Advisor

published price charts

Intraday

View AI-Driven Trading for CBIO

Interact to see
Advertisement

Why Crescent Biopharma (CBIO) Is Up +75% in the Last 30 Days

Key Takeaways

Crescent Biopharma (CBIO) stock surged +75% over the last 30 days, driven by fresh analyst buy ratings and sustained momentum from clinical trial advancements.
Over the past quarter, shares climbed +44%, fueled by the first patient dosing in the ASCEND trial and positive full-year earnings outlook highlighting cash runway into 2028.
Key catalysts include pipeline progress on CR-001 bispecific antibody, strategic partnerships, and strong analyst support amid biotech sector optimism.
Revenue growth in Q4 2025 and expanded oncology portfolio underscore improving fundamentals supporting recent price movement.

Crescent Biopharma (CBIO) Company Overview and Market Position

Crescent Biopharma, Inc. is a clinical-stage biotechnology company focused on developing next-generation oncology therapeutics, including bispecific antibodies and antibody-drug conjugates (ADCs) for solid tumors. Its lead candidate, CR-001, is a PD-1 x VEGF bispecific antibody designed to enhance anti-tumor activity. The company operates in the competitive biotechnology sector, positioning itself as a fast-follower with a pipeline targeting validated oncology targets. This exposure to high-growth immuno-oncology helps explain recent stock strength, as positive clinical momentum attracts investor interest in innovative cancer therapies.

Crescent Biopharma (CBIO) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, CBIO stock price rose sharply +75%, moving from approximately $11.10 to $19.45. The advance was volatile and trend-driven, with accelerated gains in early April amid heightened trading volume.

In the past quarter, shares gained +44%, from around $13.51 to $19.45, reflecting a steadier uptrend punctuated by key news events. Performance outpaced broader market trends, highlighting company-specific catalysts in stock analysis.

What Drove CBIO Stock Price in the Last 30 Days

The 30-day rally gained steam with Piper Sandler initiating coverage with a Buy rating on April 10, bolstering investor confidence in the oncology pipeline. This followed momentum from earlier trial progress, including regulatory clearances and ongoing ASCEND enrollment, which fueled positive market sentiment. Biotech sector tailwinds, including interest in bispecific antibodies and ADCs, amplified the move, with elevated volume signaling institutional accumulation. Analyst optimism and stock price momentum created a self-reinforcing uptrend.

What Drove CBIO Stock Performance Over the Last Quarter

Quarterly gains were anchored by clinical milestones, notably the February dosing of the first patient in the global ASCEND Phase 1/2 trial of CR-001 for advanced solid tumors. Full-year 2025 earnings revealed Q4 revenue of about $11 million, a meaningful increase, alongside cash reserves supporting operations into 2028 despite an EPS miss. Earlier partnership with Kelun-Biotech and $185 million private placement expanded the pipeline, enhancing competitive positioning. Guggenheim's Buy reaffirmation and broader institutional interest sustained the uptrend amid favorable oncology market trends.

Trending AI Robots

Tickeron’s Trending AI Robots page showcases the platform's top-performing AI-driven trading bots from a library of hundreds scanning thousands of tickers. These curated bots employ diverse strategies, such as trend-following, mean reversion, or momentum plays, across various timeframes from intraday to long-term swings. Performance metrics like win rate, profit factor, and Sharpe ratio highlight their edge, helping traders identify relevant signals for stocks like CBIO. Updated in real-time, the section filters for consistency and relevance amid market trends. Explore these tools to enhance your stock analysis and automate trading decisions.

CBIO Stock Forecast Drivers: What Investors Should Watch Next

Investors should monitor progress in the ASCEND trial, including initial safety and efficacy data from CR-001. Upcoming quarterly earnings will provide updates on revenue, cash burn, and pipeline milestones. Strategic developments like additional partnerships or regulatory filings for CR-002 and CR-003 ADCs could influence sentiment. Broader biotech trends, funding environment, and macroeconomic factors such as interest rates impacting clinical investment remain key. Risks include trial setbacks or dilution, balanced by analyst targets averaging above $25.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations

A.I.Advisor

a Summary for CBIO with price predictions

Jun 12, 2026

CBIO in downward trend: price dove below 50-day moving average on June 02, 2026

CBIO moved below its 50-day moving average on June 02, 2026 date and that indicates a change from an upward trend to a downward trend. In of 40 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on May 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CBIO as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CBIO turned negative on June 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at .

The 10-day moving average for CBIO crossed bearishly below the 50-day moving average on June 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CBIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CBIO advanced for three days, in of 232 cases, the price rose further within the following month. The odds of a continued upward trend are .

CBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.771) is normal, around the industry mean (18.720). P/E Ratio (0.000) is within average values for comparable stocks, (36.072). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.682). CBIO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (42.017) is also within normal values, averaging (357.550).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor

published Dividends

CBIO paid dividends on January 12, 2023

Crescent Biopharma Inc CBIO Stock Dividends

А quarterly dividend of $0.24 per share was paid with a record date of January 12, 2023, and an ex-dividend date of January 13, 2023. Read more...

A.I.Advisor

published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 1.9B. The market cap for tickers in the group ranges from 58 to 114.33B. VRTX holds the highest valuation in this group at 114.33B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 2%. For the same Industry, the average monthly price growth was -1%, and the average quarterly price growth was 2,383%. ELOX experienced the highest price growth at 118%, while ADTX experienced the biggest fall at -80%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 80%. For the same stocks of the Industry, the average monthly volume growth was 171% and the average quarterly volume growth was 155%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50

P/E Growth Rating: 81

Price Growth Rating: 59

SMR Rating: 94

Profit Risk Rating: 93

Seasonality Score: 12 (-100 ... +100)

View a ticker or compare two or three

Compare

CBIO

Setup

Daily Signal:

Description

Gain/Loss:

Interact to see
Advertisement

A.I. Advisor

published General Information

General Information

a clinical stage biopharmaceutical company

Industry Biotechnology

Profile

Details

Industry

Biotechnology

Address

N/A

Phone

N/A

Employees

N/A

Web

N/A